Bcl10 Antibody [BL10/411] | 33-231

Bcl10 Antibody [BL10/411] | 33-231 | Gentaur UK, US & Europe Distribution

Host: Mouse

Reactivity: Human

Homology: N/A

Immunogen: Human Bcl10 recombinant protein (epitope localized to amino acids 122-168) was used as the immunogen for this antibody.

Research Area: Apoptosis, Cancer

Tested Application: WB, Flow, IHC, IF

Application: Flow Cytometry: 0.5-1 ug/million cells
IF: 1-2 ug/ml
WB: 0.5-1 ug/ml
IHC (FFPE) : 0.5-1 ug/ml for 30 minutes at RT (1)
Prediluted format : incubate for 30 min at RT (2)
The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the Bcl10 antibody to be titered up or down for optimal performance.

1. Staining of formalin-fixed tissues requires boiling tissue sections in 10mM citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 minutes.
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required) , drip mAb solution onto the tissue section and incubate at RT for 30 min.

Specificiy: N/A

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: Protein G affinity chromatography

Clonality: Monoclonal

Clone: BL10/411

Isotype: IgG1, kappa

Conjugate: Unconjugated

Physical State: Liquid

Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide

Concentration: 0.2 mg/mL

Storage Condition: Aliquot and Store at 2-8˚C. Avoid freez-thaw cycles.

Alternate Name: Bcl-10 Antibody: CLAP, mE10, CIPER, c-E10, CARMEN, CLAP, CARD-containing molecule enhancing NF-kappa-B, Bcl-10

User Note: Optimal dilutions for each application to be determined by the researcher

BACKGROUND: Bcl10, with an N-terminal caspase recruitment domain (CARD) , is found in a number of apoptotic regulatory molecules. It was identified through its direct involvement in t (1;14) of mucosa-associated lymphoid tissue (MALT) lymphoma. Expression of Bcl10 was shown to induce NFkB activation in a NIK-dependent pathway. This antibody labels subpopulations of normal B and T cells and is a useful tool for the sub-classification of lymphomas. In MALT lymphomas with the t (1;14) translocation, while 55% of MALT lymphomas lacking this translocation exhibited the same labeling pattern, although at a much lower level.